Argos HIV drug misses main goal in mid-stage study

Your Health Matters

(Reuters) – Argos Therapeutics Inc said its experimental drug to treat HIV failed to meet its main goal in a mid-stage study, sending the company’s shares down 27 percent in premarket trade. The main goal of the trial required the drug to lower the median viral load more than a placebo in HIV-infected patients after 12 weeks of interruption of antiretroviral therapy. (Reporting by Rosmi Shaji in Bengaluru; Editing by Savio D’Souza)
Go to Source

facebookShare on Facebook
TwitterTweet
FollowFollow us
PinterestSave